Intravitreal ranibizumab for subfoveal choroidal neovascularization from age-related macular degeneration with combined severe diabetic retinopathy

So Young Han, Jeong Hun Bae, Jae Ryung Oh, Hyeong Gon Yu, Su Jeong Song

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: To evaluate the efficacy of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) from age-related macular degeneration (AMD) with combined severe diabetic retinopathy (DR). Methods: This retrospective, interventional case series included eleven patients (mean age, 70.09 years; range, 54 to 83 years) with at least severe non-proliferative DR and subfoveal CNV secondary to AMD. Each subject was treated with intravitreal injections of 0.5 mg ranibizumab. The primary outcomes included change in best-corrected visual acuity and central subfield thickness (CST) on optical coherence tomography (OCT). Results: The mean follow-up time was 16.7±14 months (range, 6 to 31 months). Mean visual acuity improved from 1.21±0.80 logarithm of the minimum angle of resolution (logMAR) to 1.0±0.6 logMAR (P=0.107), 0.95±0.62 logMAR (P=0.044), 1.10±0.68 logMAR (P=0.296), and 1.13±0.66 logMAR (P=0.838) at 1, 3, 6, and 12 months after injection, respectively. Eight patients (72.7%) gained or maintained vision (mean 0.32 logMAR), whereas three patients (27.3%) lost more than one line of vision (mean 0.51 logMAR). The mean OCT CST was 343.9±134.6 μm at baseline, and the mean CST at 1, 3, 6, 12 months after the injection was 367.8± 172.1 (P=0.864), 346.2±246.2 (P=0.857), 342±194.1 (P=0.551), and 294.2±108.3 μm (P=0.621), respectively. Conclusion: Intravitreal ranibizumab injection can be considered to be a therapy for the stabilization of subfoveal CNV secondary to AMD with combined severe DR. However, these patients might exhibit limited visual improvement after treatment.

Original languageEnglish
Pages (from-to)46-50
Number of pages5
JournalDiabetes and Metabolism Journal
Volume39
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Choroidal Neovascularization
Macular Degeneration
Diabetic Retinopathy
Intravitreal Injections
Optical Coherence Tomography
Visual Acuity
Injections
Ranibizumab
Therapeutics

Keywords

  • Choroidal neovascularization
  • Diabetic retinopathy
  • Macular degeneration

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Intravitreal ranibizumab for subfoveal choroidal neovascularization from age-related macular degeneration with combined severe diabetic retinopathy. / Han, So Young; Bae, Jeong Hun; Oh, Jae Ryung; Yu, Hyeong Gon; Song, Su Jeong.

In: Diabetes and Metabolism Journal, Vol. 39, No. 1, 01.01.2015, p. 46-50.

Research output: Contribution to journalArticle

@article{ca62eba2553342a98b11ea895e8199b8,
title = "Intravitreal ranibizumab for subfoveal choroidal neovascularization from age-related macular degeneration with combined severe diabetic retinopathy",
abstract = "Background: To evaluate the efficacy of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) from age-related macular degeneration (AMD) with combined severe diabetic retinopathy (DR). Methods: This retrospective, interventional case series included eleven patients (mean age, 70.09 years; range, 54 to 83 years) with at least severe non-proliferative DR and subfoveal CNV secondary to AMD. Each subject was treated with intravitreal injections of 0.5 mg ranibizumab. The primary outcomes included change in best-corrected visual acuity and central subfield thickness (CST) on optical coherence tomography (OCT). Results: The mean follow-up time was 16.7±14 months (range, 6 to 31 months). Mean visual acuity improved from 1.21±0.80 logarithm of the minimum angle of resolution (logMAR) to 1.0±0.6 logMAR (P=0.107), 0.95±0.62 logMAR (P=0.044), 1.10±0.68 logMAR (P=0.296), and 1.13±0.66 logMAR (P=0.838) at 1, 3, 6, and 12 months after injection, respectively. Eight patients (72.7{\%}) gained or maintained vision (mean 0.32 logMAR), whereas three patients (27.3{\%}) lost more than one line of vision (mean 0.51 logMAR). The mean OCT CST was 343.9±134.6 μm at baseline, and the mean CST at 1, 3, 6, 12 months after the injection was 367.8± 172.1 (P=0.864), 346.2±246.2 (P=0.857), 342±194.1 (P=0.551), and 294.2±108.3 μm (P=0.621), respectively. Conclusion: Intravitreal ranibizumab injection can be considered to be a therapy for the stabilization of subfoveal CNV secondary to AMD with combined severe DR. However, these patients might exhibit limited visual improvement after treatment.",
keywords = "Choroidal neovascularization, Diabetic retinopathy, Macular degeneration",
author = "Han, {So Young} and Bae, {Jeong Hun} and Oh, {Jae Ryung} and Yu, {Hyeong Gon} and Song, {Su Jeong}",
year = "2015",
month = "1",
day = "1",
doi = "10.4093/dmj.2015.39.1.46",
language = "English",
volume = "39",
pages = "46--50",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "1",

}

TY - JOUR

T1 - Intravitreal ranibizumab for subfoveal choroidal neovascularization from age-related macular degeneration with combined severe diabetic retinopathy

AU - Han, So Young

AU - Bae, Jeong Hun

AU - Oh, Jae Ryung

AU - Yu, Hyeong Gon

AU - Song, Su Jeong

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: To evaluate the efficacy of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) from age-related macular degeneration (AMD) with combined severe diabetic retinopathy (DR). Methods: This retrospective, interventional case series included eleven patients (mean age, 70.09 years; range, 54 to 83 years) with at least severe non-proliferative DR and subfoveal CNV secondary to AMD. Each subject was treated with intravitreal injections of 0.5 mg ranibizumab. The primary outcomes included change in best-corrected visual acuity and central subfield thickness (CST) on optical coherence tomography (OCT). Results: The mean follow-up time was 16.7±14 months (range, 6 to 31 months). Mean visual acuity improved from 1.21±0.80 logarithm of the minimum angle of resolution (logMAR) to 1.0±0.6 logMAR (P=0.107), 0.95±0.62 logMAR (P=0.044), 1.10±0.68 logMAR (P=0.296), and 1.13±0.66 logMAR (P=0.838) at 1, 3, 6, and 12 months after injection, respectively. Eight patients (72.7%) gained or maintained vision (mean 0.32 logMAR), whereas three patients (27.3%) lost more than one line of vision (mean 0.51 logMAR). The mean OCT CST was 343.9±134.6 μm at baseline, and the mean CST at 1, 3, 6, 12 months after the injection was 367.8± 172.1 (P=0.864), 346.2±246.2 (P=0.857), 342±194.1 (P=0.551), and 294.2±108.3 μm (P=0.621), respectively. Conclusion: Intravitreal ranibizumab injection can be considered to be a therapy for the stabilization of subfoveal CNV secondary to AMD with combined severe DR. However, these patients might exhibit limited visual improvement after treatment.

AB - Background: To evaluate the efficacy of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) from age-related macular degeneration (AMD) with combined severe diabetic retinopathy (DR). Methods: This retrospective, interventional case series included eleven patients (mean age, 70.09 years; range, 54 to 83 years) with at least severe non-proliferative DR and subfoveal CNV secondary to AMD. Each subject was treated with intravitreal injections of 0.5 mg ranibizumab. The primary outcomes included change in best-corrected visual acuity and central subfield thickness (CST) on optical coherence tomography (OCT). Results: The mean follow-up time was 16.7±14 months (range, 6 to 31 months). Mean visual acuity improved from 1.21±0.80 logarithm of the minimum angle of resolution (logMAR) to 1.0±0.6 logMAR (P=0.107), 0.95±0.62 logMAR (P=0.044), 1.10±0.68 logMAR (P=0.296), and 1.13±0.66 logMAR (P=0.838) at 1, 3, 6, and 12 months after injection, respectively. Eight patients (72.7%) gained or maintained vision (mean 0.32 logMAR), whereas three patients (27.3%) lost more than one line of vision (mean 0.51 logMAR). The mean OCT CST was 343.9±134.6 μm at baseline, and the mean CST at 1, 3, 6, 12 months after the injection was 367.8± 172.1 (P=0.864), 346.2±246.2 (P=0.857), 342±194.1 (P=0.551), and 294.2±108.3 μm (P=0.621), respectively. Conclusion: Intravitreal ranibizumab injection can be considered to be a therapy for the stabilization of subfoveal CNV secondary to AMD with combined severe DR. However, these patients might exhibit limited visual improvement after treatment.

KW - Choroidal neovascularization

KW - Diabetic retinopathy

KW - Macular degeneration

UR - http://www.scopus.com/inward/record.url?scp=84923229249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923229249&partnerID=8YFLogxK

U2 - 10.4093/dmj.2015.39.1.46

DO - 10.4093/dmj.2015.39.1.46

M3 - Article

AN - SCOPUS:84923229249

VL - 39

SP - 46

EP - 50

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 1

ER -